356 Preclinical application of a fully human TCR-mimic antibody developed to target NY-ESO-1/HLA-A02

• Yi Yang,
• Yue Zhang,
• Yuqi Zhang,
• Limin Zhao,
• Jun Du,
• W Frank An,
• Chaoshe Guo,
• Ruili Lv,
• Wanbo Tang,
• Xin Jiao,
• Pengfei Du,
• Jichao Du

Affiliations

Yi Yang

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Yue Zhang

1Stony Brook University, Stony Brook, NY, USA

Yuqi Zhang

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Limin Zhao

Shanghai Children’s Hospital, Department of Otolaryngology and Head and Neck Surgery, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Jun Du

Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China

W Frank An

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Chaoshe Guo

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Ruili Lv

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Wanbo Tang

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Xin Jiao

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Pengfei Du

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China

Jichao Du

1Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Beijing, China